Premier Veterinary Group

Study Purpose

The SOLACE study is a multicenter, observational pilot trial evaluating VETIGEL, a plant-based hemostatic hydrogel, for controlling active nosebleeds (epistaxis) in dogs.

Primary Objective:

• Assess safety and tolerability of intranasal VETIGEL during active bleeding

Secondary Objectives:

• Evaluate hemostatic effectiveness and time to bleeding control

• Monitor recurrence of bleeding

• Track patient comfort during application

• Collect data to support future clinical trials

VETIGEL rapidly forms a mechanical barrier at the bleeding site and may offer a fast, easy-to-use alternative to traditional nasal packing or systemic therapies.

Which Dogs May Qualify?

Eligible Dogs:

• Dogs of any breed or age with active unilateral or bilateral nosebleeds, including post-biopsy bleeding

Not Eligible:

• Dogs whose nasal anatomy prevents safe placement of the gel

• Dogs that have received intranasal medications in the past 7 days (e.g., phenylephrine, epinephrine, Yunnan Baiyao, antifungals, midazolam)

A veterinarian will confirm eligibility before enrollment.

What Participation Involves

Step 1: Evaluation

• Veterinary exam to confirm eligibility

• Informed consent is required before enrollment

Step 2: Treatment

• Dogs are sedated for safety and comfort

• VETIGEL is gently applied to the affected nostril(s)

• Gel remains in place 15–20 minutes before being flushed out

• A second application may be performed if needed

Step 3: Monitoring

• Veterinary team records whether bleeding stops, time to hemostasis, recurrence, and patient comfort

Step 4: Aftercare

• Dogs are discharged once stable

• Most dogs go home the same day

• Follow-up care is at the veterinarian’s discretion

What If VETIGEL Doesn’t Work?

• Additional treatments will be discussed with owners

• Study covers costs for alternative therapies, including advanced procedures if needed

• Ensures participants are not disadvantaged by joining the study

Risks & Expected Side Effects

• VETIGEL is extensively studied in clinical settings

• The most common effect is sneezing after application

• No other product-related adverse effects have been documented

• Veterinary team monitors for any unexpected reactions

Benefits of Participation

• Access to an innovative, fast-acting hemostatic treatment

• Reduced need for nasal packing or prolonged pressure

• Care from veterinary specialists

• Coverage for alternative treatments if needed

• Contribution to advancing veterinary medicine

Incentives for Owners

• Access to VETIGEL treatment for active nosebleeds

• Coverage for alternative therapies if VETIGEL is not successful

For Referring Veterinarians (rDVMs)

• Patients may return to your care after stabilization

• Detailed medical summary provided

• Participation does not interfere with long-term management

• Pilot study builds evidence for future controlled trials